NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”) reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley).

MORE ON THIS TOPIC